Nurix Therapeutics, Inc.
NRIX · Nasdaq · USD · Market cap $1.6B · 317 employees
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory condit…
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price12.85 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.45x the price, above our 2.00x limit.
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 28.42)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Distribution
- Insiders insiders sold, $74,562, latest filing 2026-11-04
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 28.42, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Nurix Therapeutics, Inc. holds its Distribution at $12.85. Consolidating, no directional conviction, held for 10 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 10 days |
| Price at the screen | $12.85 |
| Valuation | 5.86 trailing · -11.16 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.78 |
Five Screens: NRIX's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 8.10% | Below 33% | Pass |
| Interest-bearing cash | 50.28% | Below 33% | Fail |
| Receivables | 35.89% | Below 49% | Pass |
| Revenue purity | 26.16% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Nurix Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 50% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when NRIX's ethical verdict changes
Today NRIX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.45x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 14 covering, consensus Strong Buy. Average target +168%.
Clinical stage bets rarely survive revenue collapse
Developing a new cancer drug is like funding a marathon runner who has not even reached the starting line. Nurix focuses on small molecule therapies for oncology and inflammation, yet revenue has fallen 80% while losses remain total and return on equity sits at minus 80%. Analysts see upside to $34, but the business still burns cash with no approved products and an unknown moat.
The 45% gap to our fair value looks tempting on paper, yet opportunity rating stays at none. Negative forward earnings, zero profit margin and an early pipeline mean any valuation rests on future trial success that has not arrived. Ethical screen clears, but that alone does not create a durable business.
High failure rates in the clinic, repeated dilution risk and execution uncertainty keep us on the sidelines. The numbers show a company still far from cash flow, not a bargain in disguise. Analysis, not advice.
| Forward P/E | -11.2x |
| Trailing P/E | 5.9xvery cheap relative to earnings |
| EPS, trailing | 2.43 |
| EPS, forward | -1.28 |
| Revenue growth | +8,426.3%growing very fast |
| Profit margin | 42.0%highly profitable on every dollar of sales |
| Return on equity | 44.0%an exceptional return on shareholder capital |
| FCF yield | 15.00% |
| Debt to equity | 0.07minimal debt: a conservative balance sheet |
| Current ratio | 8.44comfortably covers its short-term bills |
| Beta | 1.78much more volatile than the market |
| Short interest, float | 0.18% |
| 52-week range | 12.43 - 28.23 |
| Market cap | $1.6B |
| Employees | 317 |
NRIX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to distribution since the last review.
The framework has shifted from markdown to accumulation since the last review. Since the last review it saw its composite score rise.
The framework has shifted from accumulation to markdown since the last review. Earnings landed in this window.
The framework has shifted from markup to accumulation since the last review. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer Yahoo Finance · 10d ago
- Nurix Therapeutics to Participate in Upcoming Investor Conferences Yahoo Finance · 11d ago
- Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)? Yahoo Finance · 14d ago
- Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition Yahoo Finance · 16d ago
- Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Van Houte Hans | CFO | S - Sale | 4,769 | $74,562 |
| 2026-11-02 | Ring Christine | GC | S - Sale+OE | 16,715 | $431,904 |
| 2026-10-14 | Gregory Julia P | Dir | S - Sale+OE | 22,583 | $528,528 |
| 2026-10-02 | Ring Christine | GC | S - Sale+OE | 5,786 | $134,149 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $16.28 | -6.3% | · | $937 | -6.3% |
| 2 months | $16.03 | -4.9% | · | $951 | -4.9% |
| 3 months | $15.61 | -2.3% | · | $977 | -2.3% |
| 6 months | $19.07 | -20.0% | · | $800 | -20.0% |
| 1 year | $12.79 | +19.2% | · | $1,192 | +19.2% |
| 2 years | $15.32 | -0.5% | · | $995 | -0.5% |
| 3 years | $10.14 | +50.4% | · | $1,504 | +50.4% |
| 5 years | $28.95 | -47.3% | · | $527 | -47.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NRIX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.